EP2103610A4 - Salze von imidazol-5-carbonsäurederivaten, herstellungsverfahren und verwendung davon - Google Patents

Salze von imidazol-5-carbonsäurederivaten, herstellungsverfahren und verwendung davon

Info

Publication number
EP2103610A4
EP2103610A4 EP06828254A EP06828254A EP2103610A4 EP 2103610 A4 EP2103610 A4 EP 2103610A4 EP 06828254 A EP06828254 A EP 06828254A EP 06828254 A EP06828254 A EP 06828254A EP 2103610 A4 EP2103610 A4 EP 2103610A4
Authority
EP
European Patent Office
Prior art keywords
carboxylic acid
salts
acid derivatives
therrof
imidazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP06828254A
Other languages
English (en)
French (fr)
Other versions
EP2103610A1 (de
EP2103610B1 (de
Inventor
Jianhui Guo
Dong An
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Allist Pharmaceuticals Inc
Original Assignee
Shanghai Allist Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Allist Pharmaceuticals Inc filed Critical Shanghai Allist Pharmaceuticals Inc
Publication of EP2103610A1 publication Critical patent/EP2103610A1/de
Publication of EP2103610A4 publication Critical patent/EP2103610A4/de
Application granted granted Critical
Publication of EP2103610B1 publication Critical patent/EP2103610B1/de
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EP06828254A 2006-12-06 2006-12-06 Salze von imidazol-5-carbonsäure-derivaten, herstellungsverfahren und verwendung davon Not-in-force EP2103610B1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2006/003301 WO2008067687A1 (fr) 2006-12-06 2006-12-06 Sels de dérivés d'acide imidazol-5-carboxylique, procédés de préparation et utilisation

Publications (3)

Publication Number Publication Date
EP2103610A1 EP2103610A1 (de) 2009-09-23
EP2103610A4 true EP2103610A4 (de) 2011-01-05
EP2103610B1 EP2103610B1 (de) 2011-09-21

Family

ID=39491635

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06828254A Not-in-force EP2103610B1 (de) 2006-12-06 2006-12-06 Salze von imidazol-5-carbonsäure-derivaten, herstellungsverfahren und verwendung davon

Country Status (8)

Country Link
US (1) US7943648B2 (de)
EP (1) EP2103610B1 (de)
JP (1) JP5290190B2 (de)
KR (1) KR101112515B1 (de)
AT (1) ATE525371T1 (de)
AU (1) AU2006351517B8 (de)
CA (1) CA2671816C (de)
WO (1) WO2008067687A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101024643A (zh) 2006-02-20 2007-08-29 上海艾力斯医药科技有限公司 咪唑－5－羧酸类衍生物、制备方法及其应用
CN101214242A (zh) * 2007-01-05 2008-07-09 上海艾力斯医药科技有限公司 新的药用组合物
CN101317842A (zh) * 2007-06-07 2008-12-10 上海艾力斯医药科技有限公司 一种咪唑-5-羧酸衍生物的治疗用途
CN101407511B (zh) 2007-10-11 2013-01-09 上海艾力斯生物医药有限公司 一种结晶型的咪唑-5-羧酸衍生物
CN101596189A (zh) * 2008-06-05 2009-12-09 上海艾力斯生物医药有限公司 含有咪唑-5-羧酸类衍生物的药用组合物
WO2011053546A1 (en) * 2009-10-26 2011-05-05 Lexicon Pharmaceuticals, Inc. Methods of preparing 1-(4-((1r,2s,3r)-1,2,3,4-tetrahydroxybutyl)-1h-imidazol-2-yl)ethanone
ES2620243T3 (es) * 2010-09-24 2017-06-28 Daiichi Sankyo Company, Limited Procedimiento de preparación de cristales de un derivado de cicloalqueno sustituido
CN106188012B (zh) * 2014-06-20 2018-11-30 深圳信立泰药业股份有限公司 一种阿利沙坦酯结晶及其制备方法及含有该结晶的药物组合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0535420A1 (de) * 1991-10-04 1993-04-07 Chemisch Pharmazeutische Forschungsgesellschaft m.b.H. Acylale von Imidazol-5-carbonsäurederivaten, als Angiotensin II Inhibitoren
EP1988090A1 (de) * 2006-02-20 2008-11-05 Shanghai Allist Pharmaceutical., Inc. Imidazol-5-carbonsäurederivate, herstellungsverfahren und verwendung davon

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US5138069A (en) 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5616599A (en) 1991-02-21 1997-04-01 Sankyo Company, Limited Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
US5310929A (en) * 1992-08-06 1994-05-10 E. I. Du Pont De Nemours And Company Prodrugs of imidazole carboxylic acids as angiotensin II receptor antagonists
ES2299861T3 (es) * 2003-07-31 2008-06-01 Nicox S.A. Derivados nitroxi de losartan y de otros bloqueadores similares del receptor de angiotensina ii para el tratamiento de enfermedades cardiovasculares.
AU2004270162B2 (en) * 2003-08-28 2010-05-13 Nicox S.A. Nitrosated ad nitrosylated diuretic compouds, compositions and methods of use
US20090082411A1 (en) * 2005-04-22 2009-03-26 Ryuuichi Morishita Pharmaceutical for prevention or treatment of bone metabolic disease
CN101195615B (zh) * 2006-12-06 2013-03-27 深圳市信立泰资产管理有限公司 咪唑-5-羧酸衍生物的盐、制备方法及其药物组合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0535420A1 (de) * 1991-10-04 1993-04-07 Chemisch Pharmazeutische Forschungsgesellschaft m.b.H. Acylale von Imidazol-5-carbonsäurederivaten, als Angiotensin II Inhibitoren
EP1988090A1 (de) * 2006-02-20 2008-11-05 Shanghai Allist Pharmaceutical., Inc. Imidazol-5-carbonsäurederivate, herstellungsverfahren und verwendung davon

Also Published As

Publication number Publication date
KR101112515B1 (ko) 2012-02-24
AU2006351517B8 (en) 2012-01-19
WO2008067687A1 (fr) 2008-06-12
US7943648B2 (en) 2011-05-17
JP2010511636A (ja) 2010-04-15
AU2006351517A1 (en) 2008-06-12
US20090326024A1 (en) 2009-12-31
AU2006351517B2 (en) 2011-12-22
CA2671816A1 (en) 2008-06-12
ATE525371T1 (de) 2011-10-15
EP2103610A1 (de) 2009-09-23
EP2103610B1 (de) 2011-09-21
CA2671816C (en) 2012-06-05
KR20100004917A (ko) 2010-01-13
JP5290190B2 (ja) 2013-09-18

Similar Documents

Publication Publication Date Title
EP2103610A4 (de) Salze von imidazol-5-carbonsäurederivaten, herstellungsverfahren und verwendung davon
WO2009066152A3 (en) Haloallylamine inhibitors of ssao/vap-1 and uses therefor
WO2007150026A3 (en) Purinone derivatives as hm74a agonists
NZ585219A (en) Fast release solid formulation, preparation and use thereof
EA201101672A1 (ru) Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина
EA200801998A1 (ru) ПИРИДИН[3,4-b]ПИРАЗИНОНЫ
EA200870423A1 (ru) Производные триазолпиразинов, применимые в качестве противораковых агентов
WO2006077025A3 (en) Morpholines as 5ht2c agonists
UA105229C2 (uk) Фармацевтичний склад
MX2012001953A (es) Composiciones fotosensibilizantes.
WO2008147557A3 (en) Heteroaryl substituted thiazoles and their use as antiviral agents
HK1149258A1 (en) Compounds
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
NZ597260A (en) Formulations for parenteral delivery of compounds and uses thereof comprising methylnaltrexone
EA200870302A1 (ru) 1,3-диоксанкарбоновые кислоты
WO2010011772A3 (en) Tri-cyclic pyrazolopyridine kinase inhibitors
WO2008054454A3 (en) Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents
TW200745097A (en) 4-Phenyl-thiazole-5-carboxylic acids and 4-phenyl-thiazole-5-carboxylic acid amides as PLK1 inhibitors
WO2008143240A1 (ja) 特定の有機酸を含有する経口製剤並びに経口製剤の溶出性及び化学的安定性の改善方法
EP1964842A4 (de) 5h-thieno[3,4-c]pyrrol-4,6-dionderivate gegen tumornekrosefaktor freisetzende zellen
WO2006077024A3 (en) 5-aminoindole derivatives
WO2010098600A3 (en) Substituted azole derivatives, pharmaceutical composition containing the derivatives, and method for treating parkinson's disease using the same
WO2010121675A3 (en) Thiazolyl-benzimidazoles
WO2009156837A3 (en) Amorphous form of a 3-pyrrole substituted 2-indolinone malate salt
WO2011037833A3 (en) Novel n-benzylamide substituted derivatives of 2-(acylamido)acetic acid and 2-(acylamido)propionic acids: potent neurological agents

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090706

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20101207

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 9/12 20060101ALI20101201BHEP

Ipc: A61K 31/4178 20060101ALI20101201BHEP

Ipc: C07D 403/10 20060101AFI20080627BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 9/12 20060101ALI20110228BHEP

Ipc: C07D 403/10 20060101AFI20110228BHEP

Ipc: A61K 31/4178 20060101ALI20110228BHEP

RTI1 Title (correction)

Free format text: SALTS OF IMIDAZOL-5-CARBOXYLIC ACID DERIVATIVES, PREPARATION METHODS AND USE THEREOF

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602006024615

Country of ref document: DE

Effective date: 20111201

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20110921

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110921

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110921

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110921

LTIE Lt: invalidation of european patent or patent extension

Effective date: 20110921

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20111222

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110921

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110921

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110921

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110921

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 525371

Country of ref document: AT

Kind code of ref document: T

Effective date: 20110921

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110921

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110921

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110921

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120121

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110921

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110921

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120123

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110921

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110921

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110921

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110921

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111231

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

26N No opposition filed

Effective date: 20120622

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602006024615

Country of ref document: DE

Effective date: 20120622

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111206

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111231

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120101

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111206

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20111221

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110921

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110921

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20140109 AND 20140115

REG Reference to a national code

Ref country code: FR

Ref legal event code: TP

Owner name: SALUBRIS ASSET MANAGEMENT CO. LTD., CN

Effective date: 20140108

REG Reference to a national code

Ref country code: DE

Ref legal event code: R081

Ref document number: 602006024615

Country of ref document: DE

Owner name: SALUBRIS ASSET MANAGEMENT CO. LTD., CN

Free format text: FORMER OWNER: SHANGHAI ALLIST PHARMACEUTICAL., INC., SHANGHAI, CN

Effective date: 20140102

Ref country code: DE

Ref legal event code: R082

Ref document number: 602006024615

Country of ref document: DE

Representative=s name: SCHIEBER - FARAGO, DE

Effective date: 20140102

Ref country code: DE

Ref legal event code: R081

Ref document number: 602006024615

Country of ref document: DE

Owner name: SALUBRIS ASSET MANAGEMENT CO. LTD., SHENZHEN, CN

Free format text: FORMER OWNER: SHANGHAI ALLIST PHARMACEUTICAL., INC., SHANGHAI, CN

Effective date: 20140102

Ref country code: DE

Ref legal event code: R081

Ref document number: 602006024615

Country of ref document: DE

Owner name: SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD., CN

Free format text: FORMER OWNER: SHANGHAI ALLIST PHARMACEUTICAL., INC., SHANGHAI, CN

Effective date: 20140102

Ref country code: DE

Ref legal event code: R081

Ref document number: 602006024615

Country of ref document: DE

Owner name: SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD., S, CN

Free format text: FORMER OWNER: SHANGHAI ALLIST PHARMACEUTICAL., INC., SHANGHAI, CN

Effective date: 20140102

Ref country code: DE

Ref legal event code: R082

Ref document number: 602006024615

Country of ref document: DE

Representative=s name: FARAGO PATENTANWAELTE, DE

Effective date: 20140102

Ref country code: DE

Ref legal event code: R082

Ref document number: 602006024615

Country of ref document: DE

Representative=s name: FARAGO PATENTANWALTS- UND RECHTSANWALTSGESELLS, DE

Effective date: 20140102

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20150910 AND 20150916

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 10

REG Reference to a national code

Ref country code: FR

Ref legal event code: TP

Owner name: SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD., CN

Effective date: 20151204

REG Reference to a national code

Ref country code: DE

Ref legal event code: R081

Ref document number: 602006024615

Country of ref document: DE

Owner name: SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD., CN

Free format text: FORMER OWNER: SALUBRIS ASSET MANAGEMENT CO. LTD., SHENZHEN, GUANGDONG, CN

Ref country code: DE

Ref legal event code: R082

Ref document number: 602006024615

Country of ref document: DE

Representative=s name: SCHIEBER - FARAGO, DE

Ref country code: DE

Ref legal event code: R081

Ref document number: 602006024615

Country of ref document: DE

Owner name: SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD., S, CN

Free format text: FORMER OWNER: SALUBRIS ASSET MANAGEMENT CO. LTD., SHENZHEN, GUANGDONG, CN

Ref country code: DE

Ref legal event code: R082

Ref document number: 602006024615

Country of ref document: DE

Representative=s name: FARAGO PATENTANWAELTE, DE

Ref country code: DE

Ref legal event code: R082

Ref document number: 602006024615

Country of ref document: DE

Representative=s name: FARAGO PATENTANWALTS- UND RECHTSANWALTSGESELLS, DE

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20171221

Year of fee payment: 12

Ref country code: DE

Payment date: 20171211

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20171221

Year of fee payment: 12

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602006024615

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20181206

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190702

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181206